RAUDER
This release updates the previous release that posted earlier on Tuesday 6, 2024 to add more information.
PANAMA CITY, PANAMA / ACCESSWIRE / February 8, 2024 / The forum focused on promoting public health policies based on human rights and scientific evidence.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.• Panels addressed the need for legal access to reduced-risk alternatives, such as electronic cigarettes, for millions of smokers.
• Forum's participants signed a manifesto calling on COP10 delegates to avoid prohibition and look at scientific evidence and consumers' perspectives.
Razón Autonomía Derecho A.C, RAUDER, a non-profit civil association that advocates for human rights, personal autonomy, and the free development of personality, organized the "2nd Latin American Nicotine and Risk Reduction Forum: Science, Regulation, and Activism" that took place today in Panama City. The objective was to analyze and discuss the crucial role of reduced-risk alternatives in the fight against tobacco.
The event brought together legislators, experts, doctors, scientists, and activists from across the globe. They emphasized the importance of developing public policies that aim towards harm reduction and respect for human rights, and called for a humane and effective approach, that respects consumers' rights and provides safe, science-based regulated options.
They shared different perspectives around studies and relevant practices from various countries on how alternatives such as vapor products can significantly contribute to harm reduction in smoking. Participants emphasized that their prohibition in countries such as Mexico, Brazil and Panama, has led to an increase in illegal trade and limits smokers' options to access safer alternatives.
"It is essential to recognize and regulate vapor products as reduced-risk alternatives. Prohibition not only prevents smokers from legal options but drives the black market, and gives easier access to minors, besides, all the other negative consequences that it implies," explained Rafael Lara Liy, RAUDER's director.
Doctor Marina Hoyo, a forum's panelist, said: "As health professionals, we have a responsibility to stay up to date, analyze, understand, and question the evidence. But we also need to approach our patient care from a position of empathy towards people seeking to improve their health. That's why we must consider alternatives that reduce risks. This is the foundation of a therapeutic bond that aims to truly help the individual and not stigmatize them, but rather try to alleviate their condition."
Víctor Manuel Salcedo, member of the Chamber of Representatives of Colombia, explained: "Whenever there is a health risk, regulation is necessary. We, as legislators, have the responsibility to act immediately. Our experience indicates that we should regulate, but not prohibit."
The case of other countries, such as Brazil, was also discussed. In Brazil, the ban on vapor products since 2009 has led to an uncontrolled and unsanitary illegal market, affecting millions of smokers, according to Juan José Cirión Lee, President of the organization "México y el Mundo Vapeando." We urge the Brazilian National Health Surveillance Agency (ANVISA) not to miss the opportunity to regulate alternative nicotine consumption products, considering their potential for risk reduction and respect for human rights," he added.
Studies show a significant reduction in smoking rates through reduced-risk alternatives. "The results of studies in Sweden are a clear example of what can be achieved with reduced-risk alternatives. In just 15 years, Sweden has reduced its smoking rates from 15% to 5.6% and has achieved a mortality rate from tobacco-related diseases 39.6% lower than the EU average. This success is attributed to the accessibility, acceptability, and affordability of safer alternatives, combined with balanced regulations and awareness campaigns," explained Roberto Sussman, Researcher at the UNAM Institute of Nuclear Sciences in Mexico.
RAUDER has created an online petition to strengthen the collective voice in defense of human rights, health, and legal access to nicotine alternatives. Those interested in signing the petition or supporting the cause can do so by visiting the dedicated space on the Change.org platform.
The event ended with a manifest that demands all Latin American governments to avoid prohibitions and develop science-based regulatory frameworks. "Our goal is to ensure that smokers have access to less harmful alternatives as part of a comprehensive strategy to reduce the impact of smoking on public health and that our voices are heard. This perspective is especially relevant in the context of the Tenth Conference of the Parties to the WHO Framework Convention on Tobacco Control (COP 10), taking place this week in Panama," added Rafael Lara, Director of RAUDER.
"It is important to emphasize that we share the fundamental goal of protecting public health. We advocate for the voices of consumers to be considered in discussions and decision-making that significantly impact their human rights and global health," Lara emphasized.
About RAUDER
RAUDER, short for Razón, Autonomía y Derecho, A.C., is a non-profit organization composed of experts in various fields of knowledge. Their mission is to promote and defend human rights and their respect in the daily life of society. The organization aims to influence society and public policies with the banner of respect for human rights in all aspects of social development, providing citizens with clarity about which rights they can assert concerning their governing authorities.
PRESS CONTACT:
Abroad: alejandro@nimbus.mx
Contact Information
ALEJANDRO DURAN
PR DIRECTOR
alejandro@nimbus.mx
+525534467248
SOURCE: RAUDER
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
Accurate Background Partnering with Konfir to Provide Fast, Secure Instant Employment Verification in the United Kingdom5.12.2024 09:15:00 CET | Press release
IRVINE, CA / ACCESSWIRE / December 5, 2024 / Accurate Background, headquartered in Irvine, CA, and the largest privately held and minority-owned global provider of compliant background checks, drug and health screening, and workforce monitoring solutions, has announced a new partnership with Konfir, an innovative company providing employment verification technology in the UK. This collaboration will provide Accurate's clients access to Konfir's real-time verification tools via Accurate technology. Accurate's integration of Konfir's instant employment verification API will allow candidates to aggregate real-time data from multiple data sources including Payroll, HMRC, and Open Banking, streamlining screening processes and reducing time-to-hire. In addition, Accurate will now offer enhanced fraud mitigation tools through Konfir's suite of insights helping employers identify potential hiring risks more effectively. Kevin Stone, Sales & Marketing Director at Accurate, commented: "At Accura
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
Atha Energy Identifies Numerous Outcrops Hosting High-Grade Uranium Mineralization5.12.2024 07:00:00 CET | Press release
HIGHLIGHTS Surficial mapping was conducted as part of the 2024 Angilak Exploration Program that focused on areas strictly proximal to the Lac 50 Deposit and achieved its objective of discovering high-grade uranium mineralization on surface beyond the extents of the Lac 50 Deposit's Exploration Target Model; High-grade surficial uranium mineralization was identified between Lac 48, Lac 50, Lac 52, and Lac 54 trends, collectively known as the Lac 50 Deposit, along prospective new parallel trends; Discovery of outlined outcrops containing high-grade uranium mineralization along strike from the Lac 50 Deposit provide basis for future exploration and significantly de-risk expansion efforts; A zone of extensive bedrock outcrop with radioactivity up to >60,000 counts per second (cps) - >10,000 cps is indicative of high-grade uranium mineralization - was identified over a 3-kilometre strike length. The new discovery is located between the Mushroom Lake zone on the Lac 52 trend and the Hot zone
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom